news & meetings - latest announcements & happenings | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
clinical trials and research

Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients With Familial Adenomatous Polyposis

Cancer Prevention Pharmaceuticals, Inc., a private biotech company developing novel therapeutics to prevent cancer and other diseases, and its partner Mallinckrodt Plc, a leading global specialty pharmaceutical company, today announced that CPP's pivotal phase 3 clinical trial, CPP FAP-310, of the investigational drug CPP-1X/sulindac in patients with familial adenomatous polyposis (FAP), did not meet its primary endpoint. Specifically, the reduction of time to the first occurrence of an FAP-related event for the combination of CPP-1X (eflornithine) and sulindac (a nonsteroidal anti-inflammatory drug) did not reach statistical significance compared to the two control arms. CPP FAP-310 included only active comparator arms and was the largest and longest study ever conducted in patients with FAP."While we are disappointed that the CPP FAP-310 clinical trial did not achieve its primary endpoint, we are encouraged by the data that relate to important outcome measures," said CPP CEO Jeff Jacob.
May 7, 2019

Bath woman with terminal cancer beats £20,000 fundraising goal in two days

Amy Mattingly’s diagnosis came after her baby boy was born stillborn at 24 weeks. After giving birth to Leo, the 32-year-old went on to have her entire bowel removed and was fitted with an ileostomy bag.However Amy, who lives in Bradford-Upon-Avon but previously lived in Bath, was later given the devastating news that the cancer had spread to her liver. She was told she had just months to live .But now the web designer, originally from Canada, has successfully raised more than £20,000 which will allow her to undergo a new form of radiotherapy which could extend her life.The treatment, Selective Internal Radiation Therapy, involves injecting microbeads of radiation directly into the liver. It is not currently available on the NHS and costs around £20,000. 
Jan 25, 2018

Youth Rally

Jul 20, 2020

Rare Disease Day – Home

Feb 29, 2020

Rare Disease Day at NIH 2020

Feb 28, 2020

Rare Disease Week on Capitol Hill

Feb 25, 2020

Undy Run/Walk

Feb 22, 2020

CGA Annual Meeting

Nov 3, 2019
view all (13)

    To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
    More information

    The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.